Cover Image
市場調查報告書

Glucox Biotech AB:產品平台分析

Glucox Biotech AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293922
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Glucox Biotech AB:產品平台分析 Glucox Biotech AB - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 25 Pages
簡介

Glucox Biotech AB 為製藥研究調查公司,致力於糖尿病等疾病的治療藥開發。該公司的產品尤其是用於第二型糖尿病,及高血糖症、胰島素抗性,並且從這些發生的併發症等的治療

本報告提供Glucox Biotech AB 的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關最新的新聞和發表、正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等。

Glucox Biotech AB的基本資料

  • Glucox Biotech AB概要
  • 主要資訊
  • 企業資料

Glucox Biotech AB :R&D概要

  • 主要的治療範圍

Glucox Biotech AB :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Glucox Biotech AB :開發中產品概況

  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Glucox Biotech AB :藥物簡介

  • Small Molecule to Inhibit NOX-4 for Type-2 Diabetes
  • Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke
  • Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke
  • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy
  • Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy
  • Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction
  • Small Molecule to Inhibit NOX-4 for Heart Failure

Glucox Biotech AB :開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Glucox Biotech AB :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07616CDB

Summary

Global Markets Direct's, 'Glucox Biotech AB - Product Pipeline Review - 2015', provides an overview of the Glucox Biotech AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Glucox Biotech AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Glucox Biotech AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Glucox Biotech AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Glucox Biotech AB's pipeline products

Reasons to buy

  • Evaluate Glucox Biotech AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Glucox Biotech AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Glucox Biotech AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Glucox Biotech AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Glucox Biotech AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Glucox Biotech AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Glucox Biotech AB Snapshot
    • Glucox Biotech AB Overview
    • Key Information
    • Key Facts
  • Glucox Biotech AB - Research and Development Overview
    • Key Therapeutic Areas
  • Glucox Biotech AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Glucox Biotech AB - Pipeline Products Glance
    • Glucox Biotech AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Glucox Biotech AB - Drug Profiles
    • Drug to Activate KATP Channel for Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Type-2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Heart Failure
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Glucox Biotech AB - Pipeline Analysis
  • Glucox Biotech AB - Pipeline Products by Target
  • Glucox Biotech AB - Pipeline Products by Molecule Type
  • Glucox Biotech AB - Pipeline Products by Mechanism of Action
  • Glucox Biotech AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Glucox Biotech AB, Key Information
  • Glucox Biotech AB, Key Facts
  • Glucox Biotech AB - Pipeline by Indication, 2015
  • Glucox Biotech AB - Pipeline by Stage of Development, 2015
  • Glucox Biotech AB - Monotherapy Products in Pipeline, 2015
  • Glucox Biotech AB - Preclinical, 2015
  • Glucox Biotech AB - Discovery, 2015
  • Glucox Biotech AB - Pipeline by Target, 2015
  • Glucox Biotech AB - Pipeline by Molecule Type, 2015
  • Glucox Biotech AB - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Glucox Biotech AB - Pipeline by Top 10 Indication, 2015
  • Glucox Biotech AB - Pipeline by Stage of Development, 2015
  • Glucox Biotech AB - Monotherapy Products in Pipeline, 2015
  • Glucox Biotech AB - Pipeline by Top 10 Target, 2015
  • Glucox Biotech AB - Pipeline by Top 10 Molecule Type, 2015
  • Glucox Biotech AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top